Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to target disease states, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates; FDA clearance or authorization of any products; planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of current products and product candidates; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Annual Report on Form 10-K filed on February 15, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.
Q2 2022 Key Highlights

MRD Business
- Significant clonoSEQ test volume growth of 53% vs prior year
- Received Medicare coverage for clonoSEQ DLBCL
- Signed new pan-portfolio agreement with pharma partner

Immune Medicine Business
- Pharma partnerships across diseases increasing (123% growth vs prior year)
- Genentech partnership on track with both shared and private products
- Focus on pharma partnering, TCR antigen mapping and Drug Discovery opportunities, while deferring commercialization of T-Detect

Corporate
- Focus on operational efficiencies to drive leverage
- Pursuing non-dilutive financing opportunities

Q2’ 22 Rev
$43.7M
+13% Y/Y
+13% Q/Q
MRD Business: clonoSEQ clinical testing

- Q2'22 test delivered volume +53% vs P/Y; +17% vs P/Q
  - 357 ordering accounts in Q2 (+44% vs P/Y)
  - 1,445 ordering HCPs in Q2 (+53% vs P/Y)
  - Unique patients tested increased (+56% vs P/Y)

![clonoSEQ test volume chart]

- clonoSEQ tech transfer volume from international sites

ASP expected to grow in the low-mid single digits
Solidifying Adaptive's leadership in lymphoid cancers

400K patients

- Market expansion in community
  - 11% of Q2 orders from community
  - 20% Q/Q growth in community accounts

- Penetrate deeper in institutional accounts
  - 72% of Q2 growth vs P/Y from established institutional accounts

- Multiple Myeloma in blood
  - MM in blood contributed 20% of MM Y/Y growth
  - Expect MM data in blood by YE

- Expand into NHL
  - Received Medicare coverage (DLBCL)
  - Preparing launch (DLBCL)

- Driven by sales force expansion
  + Future integration into customer ordering systems

- 20% Q/Q growth in community accounts
Data continues to emerge supporting MRD clinical utility

MRD negative patients had best outcomes, irrespective of transplant

DETERMINATION trial

“The elimination of minimal residual disease is of increasing importance in tailoring treatment, in informing clinical care, and as a treatment goal given its prognostic value for better outcomes.”
MRD Business: pharma portfolio

clonoSEQ use as an endpoint in heme clinical trials continues to grow

**Portfolio Overview**

- >60 BioPharma partners, 168 active clinical trials
- Partnership agreements include sequencing revenue plus regulatory milestones
  - Signed new pan-portfolio agreement with pharma partner in Q2’22
  - >$355M in regulatory milestones available from active and future trials
  - Recognized a $1M regulatory milestone in Q2 ‘22

**Penetration Rate by Indication**

- Overall penetration ~21%

<table>
<thead>
<tr>
<th>Indication</th>
<th>Active Heme Pharma Studies</th>
<th>51%</th>
<th>90%</th>
<th>84%</th>
<th>91%</th>
</tr>
</thead>
<tbody>
<tr>
<td>MM</td>
<td>Adaptive Studies</td>
<td>49%</td>
<td>10%</td>
<td>16%</td>
<td>9%</td>
</tr>
<tr>
<td>NHL</td>
<td>Other Studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Data as of Q4 2021. Penetration rate estimated based number of trials using clonoSEQ divided by the total number of all active trials in ALL, NHL, CLL and MM
Immune Medicine Business

Platform synergies will drive growth opportunities and generate revenue

Immune Medicine Platform

Multi-line Strategy
Multiple opportunities stemming from the Immune Receptor data

Areas of Growth
Multiple shots on goal to create value, grow and monetize our immune medicine platform across clinical applications

Pharma Services
Drug Discovery
Clinical Testing

Short-term  Medium-term  Long-term

T cells
B cells
Unlocking the value of T-cell immune receptor data at every step

Pharma Services

- TCR/Antigen Map
- ✓ Main TCR assay
- ✓ Oncology, AI, ID

Drug Discovery

- Value Creation
- ✓ T-MAP COVID
- ✓ T-MAP RSV
- T-Detect Validated diagnostic use
- Incorporated in FDA filing
- Target Discovery

Economics ($)

Value Creation

- RUO
- Regulated Use

Pharma Services

- immunoSEQ
- TCR sequencing

Drug Discovery

- Genentech
  - A Member of the Roche Group

Therapeutics
Realigning T-Detect path to commercialization

**Platform validation**

- **T-Detect COVID (EUA)**
  - Offered to consumer
  - COP studies ongoing

- **T-Detect Lyme**
  - Made available in CLIA
  - Halt commercialization

**Minimal additional investments**

**Short/mid term monetization through pharma**

- **Signal generation data**
  - Improve confirmed signals
  - Generate new signals

- **Commercialization path** focuses on opportunities with pharma partners versus clinical testing
  - T-cell response / monitoring
  - T-MAP offering

**Focusing investments on R&D and pharma partnering for TCR antigen mapping**

**Long-term positioning**

- **Clinical testing: 1 blood test, multiple indications**

  - **T-Detect**

  - Investment dependent on signal performance, clinical utility & coverage

- _Clinical Testing_
Q2 2022 Key Financial Highlights

**Total Revenue ($M)**

- **Q2 2021**: 23.0
  - MRD Business: 15.5
  - Immune Medicine Business: 7.5

- **Q2 2022**: 22.4
  - MRD Business: 21.3
  - Immune Medicine Business: 1.1

  +13%

**Immune Medicine Revenue ($M)**

- **Q2 2021**: 23.0
  - Drug Discovery: -3.4
  - Pharma*: +3.7
  - T-Detect: -1.0

- **Q2 2022**: 22.4

**MRD Revenue ($M)**

- **Q2 2021**: 15.5
- **Q2 2022**: $21.3

  +$6.3

  [Clinical testing
  pharma sequencing]

  -$0.5

  All $ and % figures are rounded

  * Includes Academics
Q2 2022 Key Financial Highlights Cont.

Strong Balance Sheet
- ~$450M in cash, cash equivalents and marketable securities as of 06/30/2022
- Quarterly cash burn ~$55M in 2H 2022

FY 2022 Revenue Guidance
- Reiterate FY range $185M-$195M
  - MRD and Immune Medicine represents ~50% / 50% of total revenue at mid-point of range

FY 2022 Opex Guidance
- Updated FY range $410M-$415M vs. $425M-$435M previously

All $ and % figures are rounded
Updated Key Catalysts 2022

COVID T-cell response: focus on correlate of protection
Scale T-MAP and drug discovery opportunities with pharma
Genentech collaboration:
✓ Selected TCR candidate to progress as a potential therapeutic product candidate
☐ Deliver 2 additional TCR data packages for consideration
☐ Establish private product specifications

Medicare coverage of DLBCL
✓ Expand adoption of MRD status as a co-/primary clinical endpoint
■ Read-out data for use in blood in MM/DLBCL
Thank You.